Navigation Links
Data From LigoCyte's Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
Date:4/28/2010

offers a thorough picture of the opportunities, challenges and discoveries associated with vaccine development, production and distribution. The conference is sponsored by the National Foundation for Infectious Diseases (NFID) and held in collaboration with the Center for Biologics Evaluation and Research/Food and Drug Administration, Centers for Disease Control and Prevention, Center for Vaccine Development of the University of Maryland, Fondation Merieux, International Association for Biologicals, International Society for Vaccines, International Vaccine Institute, National Institute for Allergy and Infectious Diseases, The Jenner Society, Sabin Vaccine Institute and United States Department of Agriculture. Founded in 1973, NFID is a non-profit organization dedicated to educating the public and healthcare professionals about the causes, treatment and prevention of infectious diseases.

About LigoCyte

LigoCyte is a private, clinical-stage biotechnology company focused on developing novel vaccines for gastrointestinal and respiratory indications. LigoCyte's expertise in virus-like particle technology supports a pipeline of enhanced product candidates, including vaccines against norovirus, influenza and respiratory syncytial virus. LigoCyte has funded its product development efforts through a mix of private investment as well as grants and contracts administered through the National Institutes of Health and the U.S. Department of Defense, including a recent $3.6 million commitment from the agency. LigoCyte's investors include Forward Ventures, JAFCO, Novartis Venture Fund, Fidelity Biosciences, MedImmune Ventures, Athenian Venture Partners and MC Life Sciences Ventures (Mitsubishi International Corporation). The company closed its most recent financing in April 2010 from its existing venture investors. GlaxoSmit
'/>"/>

SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioMedix Receives Clinical Approval for TRAKnet Software
2. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
3. Suzie Williams, CP Joins Orthocare Innovations as Clinical Services Manager
4. Kristalose(R) Clinical Data to Be Presented at Digestive Disease Week(R) Meeting
5. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
6. AFFiRiS AG: Alzheimers Vaccine AD02 Already in Clinical Phase II
7. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
8. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
9. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
10. Creating Healthcare Reform from the Inside Out Through Supply Chain Best Practices that Improve Financial and Clinical Performance is Focus of 2010 GHX Supply Chain Summit
11. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Calif. , Aug. 28, 2014  In anticipation of ... infographic is being made available for the first time. ... Diego offers a snapshot of ... Highlighting everything from the latest employment statistics to ... made San Diego such a vital ...
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek,Pharmaceuticals Corporation ... preclinical animal data showing that the,administration of a ... on the survival of certain brain,cells following a ... the,repair of damaged DNA via the activation and ...
... study appearing in the March,22 New England Journal ... Healths National Institute of Arthritis and,Musculoskeletal and Skin ... gene and the inflammatory skin,condition vitiligo, as well ... is a chronic condition in which melanocytes (the ...
Cached Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
(Date:8/29/2014)... Auckland, NZ (PRWEB) August 29, 2014 ... of Greg Allen to Chief Executive Officer effective from ... Chief Technology Officer for Winscribe. , “During this time ... Winscribe than Greg Allen,” said Matthew Weavers, Winscribe’s Founder ... leader with a wealth of commercial, IT and management ...
(Date:8/28/2014)... 2014 Career Step, an online provider ... new video designed to help students and career seekers ... billing field. The video details what medical coders and ... professionals, and the education requirements for entering this field. ... often overlooked when people are considering a career in ...
(Date:8/28/2014)... FL (PRWEB) August 29, 2014 ... that brings pharmaceutical industry precision to the development ... zoning approval for its primary location in Sarasota ... and decisively with a total commitment to attracting ... forward to creating," says David Wright, President and ...
(Date:8/28/2014)... When David Gergen, President of ... Mark Brnovich, was asked to publicly support Mr. Brnovich ... Attorney General seat in the State of Arizona, Mr. ... of Cardinal Hall of Fame wide receiver Roy Green ... Mark Walczak. Green, Kennard and Walczak are members of ...
(Date:8/28/2014)... Farmington, New York (PRWEB) August 29, 2014 ... Autumn as they will be traveling around the country ... with a final show in November. The New Energy ... exhibit sharing their timber frame design and build expertise, ... addition, Drake Ambrosino , New Energy Works’ Mid-West ...
Breaking Medicine News(10 mins):Health News:Winscribe Names Greg Allen as CEO 2Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3
... ... recent launch of accounts on the popular social networking sites, Facebook, Twitter, and LinkedIn. ... Las Vegas, ... consultations, diagnoses, prescriptions, and doctors, excuses for work and school, expands its outreach to ...
... SEATTLE, Aug. 27 IDRI (Infectious Disease Research ... in Sudan to test its leishmaniasis vaccine candidate for ... complication of visceral leishmaniasis (VL) which is observed in ... predominantly affecting children. This trial reflects IDRI,s commitment to ...
... PRINCETON, N.J., Aug. 27 More than 160 ... are coming together at educational summits sponsored this fall by ... Continuing Education (CBCE). For the fifth year, the Inhibitor Education ... professionals and fellow patients to address pertinent topics such as ...
... rates similar to those with deceased donor transplant organs, ... People with kidney disease may do just as well ... from a deceased donor, new research has found. , ... 1,239 patients who had either received a kidney transplant ...
... Japan, Aug. 27 Hisamitsu Pharmaceutical Co., Inc. (TSE: ... completion of the tender offer for all outstanding shares of Noven ... price per share of $16.50. The subsequent offering period expired ... 2009 and was not extended. , , ...
... , MAPLE GROVE, Minn., Aug. 27 NeuroVasx, Inc., ... hemorrhagic and ischemic stroke, announced today that it has received approval ... Canada,s Therapeutic Products Directorate. In addition to Canadian regulatory approval, ... , Eric B. Timko, President and Chief Executive ...
Cached Medicine News:Health News:KoolDocs.com Increases Online Presence through Social Networking Premium Online Medical Consultation Service Now on Facebook, Twitter, and LinkedIn 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 2Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 3
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Medicine Products: